Overview

Oral Pyrophosphate Absorption in PXE Disease

Status:
Withdrawn
Trial end date:
2021-04-01
Target enrollment:
Participant gender:
Summary
Pyrophosphate is an endogenous, non-toxic metabolite inhibiting soft tissue calcification. The aim of our study is to find optimal dosing and safety of oral disodium-PPi (Na2H2PPi). Absorption curves (pharmacokinetics), AUC0-t, Cmax and Tmax for PPi and phosphate will be provided for healthy controls and PXE-patients both fasting and with standard meal intake.
Phase:
Phase 2
Details
Lead Sponsor:
Tampere University Hospital
Collaborators:
Hungarian Academy of Sciences
UMC Utrecht